Replies to post #2218 on Idenix Pharmaceuticals (IDIX)

[keitern]

Seems IDIX's restructuring to a percentage of worldwide sales may have been a smart move, considering the slow uptake in the US.

[DewDiligence]

Tyzeka US Scripts

The 11/16 numbers rebounded and are comparable to
those in the week of 10/26. Please see separate post
for rolling four-week script and market-share figures,
which are less volatile than the weekly figures (c/o rkrw).

NRx=number of new prescriptions; TRx=number
of total prescriptions (new+renewal). For recently
launched drugs, the trend in NRx is an indicator of
what can be expected for TRx with a modest time lag.
NRx% and TRx% are calculated as NRx and TRx
divided by the number of new and total prescriptions,
respectively, for all drugs in the HBV category. (A
prescription is counted as new whenever it is newly
written, even if the patient is already taking the drug.)

 
 Date  NRx TRx NRx% TRx% 
 Nov16 122 349 5.7% 4.4% 
 Nov09  83 249 3.7% 3.1% 
 Nov02 112 315 4.9% 3.9% 
 Oct26 129 356 5.6% 4.4% 
 Oct19  96 245 4.4% 3.2% 
 Oct12 126 304 5.3% 3.8% 
 Oct05 139 314 5.9% 4.0% 
 Sep28 116 299 4.9% 3.7% 
 Sep21  87 252 3.8% 3.3% 
 Sep14 100 277 4.3% 3.6% 
 Sep07  82 242 3.7% 3.1% 
 Aug31  99 318 4.1% 4.0% 
 Aug24 101 280 4.8% 3.6% 
 Aug17 101 254 4.5% 3.3% 
 Aug10 125 270 5.4% 3.5% 
 Aug03 123 265 5.3% 3.4% 
 Jul27 120 268 5.3% 3.5% 
 Jul20 102 225 4.7% 3.0% 
 Jul13 115 286 5.0% 3.7% 
 Jun29  86 214 3.8% 2.8% 
 Jun22  78 197 3.6% 2.7% 
 Jun15  91 212 4.0% 2.8% 
 Jun08  80 191 3.5% 2.5% 
 Jun01  65 167 3.4% 2.5% 
 May25  79 169 3.6% 2.3% 
 May18  80 152 3.7% 2.2% 
 May11  93 191 4.4% 2.6% 
 May04  92 188 4.1% 2.5% 
 Apr27  80 161 3.6% 2.2% 
 Apr20  76 146 3.6% 2.1% 
 Apr13  61 135 2.9% 1.9% 
 Apr06  82 137 3.9% 1.9% 
 Mar30  87 142 3.9% 2.0% 
 Mar23  55  90 2.7% 1.3% 
 Mar16  54 103 2.4% 1.4%